Cost of disorders of the brain in Europe 2010

European Neuropsychopharmacology

Volumn 21, Issue 10, 2011, Pages 718-779

  Gustavsson, Anders ^a   Svensson, Mikael ^b   Jacobi, Frank ^c   Allgulander, Christer ^d   Alonso, Jordi ^e   Beghi, Ettore ^f   Dodel, Richard ^g   Ekman, Mattias ^a   Faravelli, Carlo ^h   Fratiglioni, Laura ⁱ   Gannon, Brenda ^j   Jones, David Hilton ^k   Jennum, Poul ^l   Jordanova, Albena ^m,n,o   Jönsson, Linus ^a   Karampampa, Korinna ^a   Knapp, Martin ^p,q   Kobelt, Gisela ^r,s   Kurth, Tobias ^t   Lieb, Roselind ^u   Linde, Mattias ^v,w   Ljungcrantz, Christina ^a   Maercker, Andreas ^x   Melin, Beatrice ^y   Moscarelli, Massimo ^z,aa   Musayev, Amir ^a   Norwood, Fiona ^ab   Preisig, Martin ^ac   Pugliatti, Maura ^ad   Rehm, Juergen ^c,ae   Salvador Carulla, Luis ^af,ag   Schlehofer, Brigitte ^ah   Simon, Roland ^ai   Steinhausen, Hans Christoph ^u,x,aj   Stovner, Lars Jacob ^v   Vallat, Jean Michel ^ak   den Bergh, Peter Van ^al   van Os, Jim ^q,am   Vos, Pieter ^an   Xu, Weili ⁱ   Wittchen, Hans Ulrich ^c   Jönsson, Bengt ^ao   Olesen, Jes ^ap   more..

^a OptumInsight   (Sweden)

^b KARLSTAD UNIVERSITY   (Sweden)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e HOSPITAL DEL MAR   (Spain)

^f MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^g PHILIPPS UNIVERSITY MARBURG   (Germany)

^h UNIVERSITY OF FLORENCE   (Italy)

ⁱ KAROLINSKA INSTITUTE   (Sweden)

^j UNIVERSITY OF LEEDS   (United Kingdom)

^k JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^l Centre for Sleep Medicine   (Denmark)

^m DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

ⁿ UNIVERSITY OF ANTWERP   (Belgium)

^o MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^p LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^q KING'S COLLEGE LONDON   (United Kingdom)

^r LUND UNIVERSITY   (Sweden)

^s European Health Economics   (France)

^t HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^u UNIVERSITY OF BASEL   (Switzerland)

^v NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^w TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^x UNIVERSITY OF ZURICH   (Switzerland)

^y UMEÅ UNIVERSITY   (Sweden)

^z International Centre of Mental Health Policy and Economics   (Italy)

^aa HARVARD MEDICAL SCHOOL   (United States)

^ab KING S COLLEGE HOSPITAL   (United Kingdom)

^ac LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^ad UNIVERSITY OF SASSARI   (Italy)

^ae CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^af Asociación Científica PSICOST   (Spain)

^ag UNIVERSITY OF CÁDIZ   (Spain)

^ah GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^ai EUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION   (Portugal)

^aj AALBORG UNIVERSITY HOSPITAL   (Denmark)

^ak LIMOGES UNIVERSITY HOSPITAL   (France)

^al CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^am MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^an RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^ao STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

^ap GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADDICTION; ANXIETY DISORDER; ARTICLE; BRAIN DISEASE; BRAIN TUMOR; COMPARATIVE STUDY; COST OF ILLNESS; DEMENTIA; DEVELOPMENTAL DISORDER; EATING DISORDER; EPILEPSY; EUROPE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; MENTAL DEFICIENCY; MIGRAINE; MOOD DISORDER; MULTIPLE SCLEROSIS; NEUROMUSCULAR DISEASE; PARKINSON DISEASE; PERSONALITY DISORDER; POPULATION DYNAMICS; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; SLEEP DISORDER; SOMATOFORM DISORDER; STATISTICAL ANALYSIS; STROKE; SYSTEMATIC REVIEW; TRAUMATIC BRAIN INJURY; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN DISEASES; CHILD; CHILD, PRESCHOOL; COST OF ILLNESS; EUROPE; FEMALE; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; INFANT; INFANT, NEWBORN; MALE; MENTAL DISORDERS; MIDDLE AGED; PREVALENCE; PUBLIC HEALTH;

EID: 80053496448     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2011.08.008     Document Type: Article

References (441)

1. Abela A., Mamo J., Aquilina C., Scerri C. Estimated prevalance of dementia in the Maltese Islands. Malta Med. J. 2007, 19:23-26.
2. Abu-Baker A., Rouleau G.A. Oculopharyngeal muscular dystrophy: recent advances in the understanding of the molecular pathogenic mechanisms and treatment strategies. Biochim. Biophys. Acta 2007, 1772:173-185.
3. Acarturk C., Smit F., de Graaf R., van Straten A., Ten Have M., Cuijpers P. Economic costs of social phobia: a population-based study. J. Affect. Disord. 2009, 115:421-429.
4. AccessEconomics The Cost of Muscular Dystrophy. Muscular Dystrophy Association 2007, AccessEconomics.
5. Adelow C., Andell E., Amark P., Andersson T., Hellebro E., Ahlbom A., Tomson T. Newly diagnosed single unprovoked seizures and epilepsy in Stockholm, Sweden: first report from the Stockholm Incidence Registry of Epilepsy (SIRE). Epilepsia 2009, 50:1094-1101.
6. af Geijerstam J.L., Britton M. Mild head injury - mortality and complication rate: meta-analysis of findings in a systematic literature review. Acta Neurochir. (Wien.) 2003, 145:843-850.
7. Ancoli-Israel S. Epidemiology of sleep disorders. Clin. Geriatr. Med. 1989, 5:347-362.
8. Ancoli-Israel S., Klauber M.R., Stepnowsky C., Estline E., Chinn A., Fell R. Sleep-disordered breathing in African-American elderly. Am. J. Respir. Crit. Care Med. 1995, 152:1946-1949.
9. Andersen K., Lolk A., Nielsen H., Andersen J., Olsen C., Kragh-Sorensen P. Prevalence of very mild to severe dementia in Denmark. Acta Neurol. Scand. 1997, 96:82-87.
10. Andlin-Sobocki P., Rehm J. Cost of addiction in Europe. Eur. J. Neurol. 2005, 12(Suppl. 1):28-33.
11. Andlin-Sobocki P., Rossler W. Cost of psychotic disorders in Europe. Eur. J. Neurol. 2005, 12(Suppl. 1):74-77.
12. Andlin-Sobocki P., Wittchen H.U. Cost of affective disorders in Europe. Eur. J. Neurol. 2005, 12(Suppl. 1):34-38.
13. Andlin-Sobocki P., Wittchen H.U. Cost of anxiety disorders in Europe. Eur. J. Neurol. 2005, 12(Suppl. 1):39-44.
14. Andlin-Sobocki P., Jonsson B., Wittchen H.U., Olesen J. Cost of disorders of the brain in Europe. Eur. J. Neurol. 2005, 12(Suppl. 1):1-27.
15. Andrée, C., Stovner, L., Steiner, T., et al., 2011. The Eurolight study on the impact and burden of primary headache in Europe - Description of the Methodology. Manuscript JHP.
16. Ares B., Prieto J.M., Lema M., Dapena D., Arias M., Noya M. Prevalence of multiple sclerosis in Santiago de Compostela (Galicia, Spain). Mult. Scler. 2007, 13:262-264.
17. Atance Martinez J.C., Yusta I.A., Grupeli Gardel B.E. Costs study in Alzheimer's disease. Rev. Clin. Esp. 2004, 204:64-69.
18. Balakrishnan R., Allender S., Scarborough P., Webster P., Rayner M. The burden of alcohol-related ill health in the United Kingdom. J. Public Health (Oxf.) 2009, 31:366-373.
19. Balasa R., Feier C., Dan M., Motataianu A., Balaianu M., Chebut C., Constantin Z.B., Pascu I. The prevalence of multiple sclerosis in Mures County, Central Romania. Rev. Rom. Neurol. 2007, 6:80-84.
20. Baldwin C.M., Griffith K.A., Nieto F.J., O'Connor G.T., Walsleben J.A., Redline S. The association of sleep-disordered breathing and sleep symptoms with quality of life in the Sleep Heart Health Study. Sleep 2001, 24:96-105.
21. Baldwin C.M., Ervin A.M., Mays M.Z., Robbins J., Shafazand S., Walsleben J., Weaver T. Sleep disturbances, quality of life, and ethnicity: the Sleep Heart Health Study. J. Clin. Sleep Med. 2010, 6:176-183.
22. Banerjee P.N., Filippi D., Allen H.W. The descriptive epidemiology of epilepsy-a review. Epilepsy Res. 2009, 85:31-45.
23. Barth F., Baum B., Bremen D., Meuser T., Jost W.H. Indirect costs in idiopathic Parkinson's disease. Fortschr. Neurol. Psychiatr. 2005, 73:187-191.
24. Batelaan N., Smit F., de Graaf R., van Balkom A., Vollebergh W., Beekman A. Economic costs of full-blown and subthreshold panic disorder. J. Affect. Disord. 2007, 104:127-136.
25. Baumgaertel A., Wolraich M.L., Dietrich M. Comparison of diagnostic criteria for attention deficit disorders in a German elementary school sample. J. Am. Acad. Child Adolesc. Psychiatry 1995, 34:629-638.
26. Baumhackl U., Eibl G., Ganzinger U., Hartung H.P., Mamoli B., Pfeiffer K.P., Fazekas F., Vass K. Prevalence of multiple sclerosis in Austria. Results of a nationwide survey. Neuroepidemiology 2002, 21:226-234.
27. Bdzan L.B., Turczynski J., Szabert K. Prevalence of dementia in a rural population. Psychiatr. Pol. 2007, 41:181-188.
28. Bebbington P.E., Angermeyer M., Azorin J.M., Brugha T., Kilian R., Johnson S., Toumi M., Kornfeld A. The European Schizophrenia Cohort (EuroSC): a naturalistic prognostic and economic study. Soc. Psychiatry Psychiatr. Epidemiol. 2005, 40:707-717.
29. Beesdo K., Hofler M., Leibenluft E., Lieb R., Bauer M., Pfennig A. Mood episodes and mood disorders: patterns of incidence and conversion in the first three decades of life. Bipolar. Disord. 2009, 11:637-649.
30. Beesdo K., Pine D.S., Lieb R., Wittchen H.U. Incidence and risk patterns of anxiety and depressive disorders and categorization of generalized anxiety disorder. Arch. Gen. Psychiatry 2010, 67:47-57.
31. Beghi E., Monticelli M.L., Monza G., Sessa A., Zarrelli M. Antiepileptic drugs as 'tracers' of disease. A calculation of the prevalence of epilepsy through an analysis of drug consumption. The Group for the Study of Epilepsy in General Practice. Neuroepidemiology 1991, 10:33-41.
32. Beghi E., Garattini L., Ricci E., Cornago D., Parazzini F. Direct cost of medical management of epilepsy among adults in Italy: a prospective cost-of-illness study (EPICOS). Epilepsia 2004, 45:171-178.
33. Behan C., Kennelly B., O'Callaghan E. The economic cost of schizophrenia in Ireland: a cost of illness study. Ir. J. Psych Med. 2008, 25:80-87.
34. Beilmann A., Napa A., Soot A., Talvik I., Talvik T. Prevalence of childhood epilepsy in Estonia. Epilepsia 1999, 40:1011-1019.
35. Benavente I., Rubio E., Morales C., Tajada N., Tamargo P. Prevalence of epilepsy amongst adolescents in Huesca, Spain: a community-based study. Eur. J. Neurol. 2009, 16:1138-1143.
36. Bencsik K., Rajda C., Klivenyi P., Jardanhazy T., Vecsei L. The prevalence of multiple sclerosis in the Hungarian city of Szeged. Acta Neurol. Scand. 1998, 97:315-319.
37. Benedikz J., Stefansson M., Guomundsson J., Jonasdottir A., Fossdal R., Gulcher J., Stefansson K. The natural history of untreated multiple sclerosis in Iceland. A total population-based 50year prospective study. Clin. Neurol. Neurosurg. 2002, 104:208-210.
38. Bentzen J., Flachs E.M., Stenager E., Bronnum-Hansen H., Koch-Henriksen N. Prevalence of multiple sclerosis in Denmark 1950-2005. Mult. Scler. 2010, 16:520-525.
39. Berg J., Stovner L.J. Cost of migraine and other headaches in Europe. Eur. J. Neurol. 2005, 12(Suppl. 1):59-62.
40. Berg J., Tagliaferri F., Servadei F. Cost of trauma in Europe. Eur. J. Neurol. 2005, 12(Suppl. 1):85-90.
41. Berg J., Lindgren P., Fredrikson S., Kobelt G. Costs and quality of life of multiple sclerosis in Sweden. Eur. J. Health Econ. 2006, 7(Suppl. 2):S75-S85.
42. Bertelli M., Hassiotis A., Deb S., Salvador-Carulla L. New contributions of psychiatric research in the field of intellectual disabilities. Adv. Psychiatry 2009, 3:37-43.
43. Berto P., Tinuper P., Viaggi S. Cost-of-illness of epilepsy in Italy. Data from a multicentre observational study (Episcreen). PharmacoEconomics 2000, 17:197-208.
44. Bielen I., Cvitanovic-Sojat L., Bergman-Markovic B., Kosicek M., Planjar-Prvan M., Vuksic L., Miketek G., Matek P. Prevalence of epilepsy in Croatia: a population-based survey. Acta Neurol. Scand. 2007, 116:361-367.
45. Bixler E.O., Vgontzas A.N., Ten H.T., Tyson K., Kales A. Effects of age on sleep apnea in men: I. Prevalence and severity. Am. J. Respir. Crit. Care Med. 1998, 157:144-148.
46. Bixler E.O., Vgontzas A.N., Lin H.M., Ten H.T., Leiby B.E., Vela-Bueno A., Kales A. Association of hypertension and sleep-disordered breathing. Arch. Intern. Med. 2000, 160:2289-2295.
47. Bixler E.O., Vgontzas A.N., Lin H.M., Ten H.T., Rein J., Vela-Bueno A., Kales A. Prevalence of sleep-disordered breathing in women: effects of gender. Am. J. Respir. Crit. Care Med. 2001, 163:608-613.
48. Bixler E.O., Vgontzas A.N., Lin H.M., Liao D., Calhoun S., Vela-Bueno A., Fedok F., Vlasic V., Graff G. Sleep disordered breathing in children in a general population sample: prevalence and risk factors. Sleep 2009, 32:731-736.
49. Bliwise D.L., Bliwise N.G., Partinen M., Pursley A.M., Dement W.C. Sleep apnea and mortality in an aged cohort. Am. J. Public Health 1988, 78:544-547.
50. Blomqvist P., Lycke J., Strang P., Tornqvist H., Ekbom A. Brain tumours in Sweden 1996: care and costs. J. Neurol. Neurosurg. Psychiatry 2000, 69:792-798.
51. Bluestein D., Rutledge C.M., Healey A.C. Psychosocial correlates of insomnia severity in primary care. J. Am. Board Fam. Med. 2010, 23:204-211.
52. Boada M., Pena-Casanova J., Bermejo F., Guillen F., Hart W.M., Espinosa C., Rovira J. Costs of health care resources of ambulatory-care patients diagnosed with Alzheimer's disease in Spain. Med. Clin. (Barc.) 1999, 113:690-695.
53. Bondy M.L., Scheurer M.E., Malmer B., Barnholtz-Sloan J.S., Davis F.G., Il'yasova D., Kruchko C., McCarthy B.J., Rajaraman P., Schwartzbaum J.A., Sadetzki S., Schlehofer B., Tihan T., Wiemels J.L., Wrensch M., Buffler P.A. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer 2008, 113:1953-1968.
54. Börjesson-Hanson A., Edin E., Gislason T., Skoog I. The prevalence of dementia in 95year olds. Neurology 2004, 63:2436-2438.
55. Bostrom I., Callander M., Kurtzke J.F., Landtblom A.M. High prevalence of multiple sclerosis in the Swedish county of Varmland. Mult. Scler. 2009, 15:1253-1262.
56. Boström F., Jonsson L., Minthon L., Londos E. Patients with Lewy body dementia use more resources than those with Alzheimer's disease. Int. J. Geriatr. Psychiatry 2007, 22:713-719.
57. Boyle A., Melville C.A., Morrison J., Allan L., Smiley E., Espie C.A., Cooper S.A. A cohort study of the prevalence of sleep problems in adults with intellectual disabilities. J. Sleep Res. 2010, 19:42-53.
58. Bray F., Sankila R., Ferlay J., Parkin D.M. Estimates of cancer incidence and mortality in Europe in 1995. Eur. J. Cancer 2002, 38:99-166.
59. Brayne C. Incidence of dementia in England and Wales: the MRC Cognitive Function and Ageing Study. Alzheimer Dis. Assoc. Disord. 2006, 20:S47-S51.
60. Brodtkorb E., Sjaastad O. Epilepsy prevalence by individual interview in a Norwegian community. Seizure 2008, 17:646-650.
61. Broman J.E., Mallon L., Hetta J. Restless legs syndrome and its relationship with insomnia symptoms and daytime distress: epidemiological survey in Sweden. Psychiatry Clin. Neurosci. 2008, 62:472-475.
62. Brorson L.O. Epilepsy among children and adolescents. A clinical, psychometric and social study in the province of Uppsala 1970, 1-84.
63. Brower K.J., Perron B.E. Prevalence and correlates of withdrawal-related insomnia among adults with alcohol dependence: results from a national survey. Am. J. Addict. 2010, 19:238-244.
64. Casado V., Martinez-Yelamos S., Martinez-Yelamos A., Carmona O., Alonso L., Romero L., Moral E., Gubieras L., Arbizu T. Direct and indirect costs of Multiple Sclerosis in Baix Llobregat (Catalonia, Spain), according to disability. BMC Health Serv. Res. 2006, 6:143.
65. Cassidy J.D., Carroll L.J., Peloso P.M., Borg J., von Holst H., Holm L., Kraus J., Coronado V.G. WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury. J. Rehabil. Med. 2004, 28-60.
66. Cats E.A., van der Pol W.L., Piepers S., Franssen H., Jacobs B.C., van den Berg-Vos R.M., Kuks J.B., van Doorn P.A., van Engelen B.G., Verschuuren J.J., Wokke J.H., Veldink J.H., van den Berg L.H. Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology 2010, 75:818-825.
67. Cavallo M.C., Fattore G. The economic and social burden of Alzheimer disease on families in the Lombardy region of Italy. Alzheimer Dis. Assoc. Disord. 1997, 11:184-190.
68. Cavazzuti G.B. Epidemiology of different types of epilepsy in school age children of Modena, Italy. Epilepsia 1980, 21:57-62.
69. Chasens E.R., Twerski S.R., Yang K., Umlauf M.G. Sleepiness and health in midlife women: results of the National Sleep Foundation's 2007 Sleep in America poll. Behav. Sleep Med. 2010, 8:157-171.
70. Chisholm D., Diehr P., Knapp M., Patrick D., Treglia M., Simon G. Depression status, medical comorbidity and resource costs. Evidence from an international study of major depression in primary care (LIDO). Br. J. Psychiatry 2003, 183:121-131.
71. Christensen J., Vestergaard M., Pedersen M.G., Pedersen C.B., Olsen J., Sidenius P. Incidence and prevalence of epilepsy in Denmark. Epilepsy Res. 2007, 76:60-65.
72. Cockerell O.C., Hart Y.M., Sander J.W., Shorvon S.D. The cost of epilepsy in the United Kingdom: an estimation based on the results of two population-based studies. Epilepsy Res. 1994, 18:249-260.
73. Coduras A., Rabasa I., Frank A., Bermejo-Pareja F., Lopez-Pousa S., Lopez-Arrieta J.M., Del L.J., Leon T., Rejas J. Prospective one-year cost-of-illness study in a cohort of patients with dementia of alzheimer's disease type in Spain: the ECO study. J. Alzheimers Dis. 2010, 19(2):601-615.
74. Coid J., Yang M., Tyrer P., Roberts A., Ullrich S. Prevalence and correlates of personality disorder in Great Britain. Br. J. Psychiatry 2006, 188:423-431.
75. Coyle D., Godfrey C., Hardman G., Raistrick D. Costing substance misuse services. Addiction 1997, 92:1007-1015.
76. Cubo E., Alvarez E., Morant C., de Pedro C.J., Martinez M.P., Genova R., Freire J.M. Burden of disease related to Parkinson's disease in Spain in the year 2000. Mov. Disord. 2005, 20:1481-1487.
77. Cuijpers P., Smit F., Oostenbrink J., de Graaf R., Ten Have M., Beekman A. Economic costs of minor depression: a population-based study. Acta Psychiatr. Scand. 2007, 115:229-236.
78. Cuijpers P., Smit F., Penninx B.W., de Graaf R., Ten Have M., Beekman A. Economic costs of neuroticism: a population-based study. Arch. Gen. Psychiatry 2010, 67:1086-1093.
79. Das G.R., Guest J.F. Annual cost of bipolar disorder to UK society. Br. J. Psychiatry 2002, 180:227-233.
80. Dauvilliers Y., Montplaisir J., Molinari N., Carlander B., Ondze B., Besset A., Billiard M. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology 2001, 57:2029-2033.
81. Dauvilliers Y., Bazin M., Ondze B., Bera O., Bazin M., Besset A., Billiard M. Severity of narcolepsy among French of different ethnic origins (south of France and Martinique). Sleep 2002, 25:50-55.
82. de la Court, Breteler M.M., Meinardi H., Hauser W.A., Hofman A. Prevalence of epilepsy in the elderly: the Rotterdam Study. Epilepsia 1996, 37:141-147.
83. De Ronchi D., Berardi D., Menchetti M., Ferrari G., Serretti A., Dalmonte E., Fratiglioni L. Occurrence of cognitive impairment and dementia after the age of 60: a population-based study from Northern Italy. Dement. Geriatr. Cogn. Disord. 2005, 19:97-105.
84. De Sä J., Paulos A., Mendes H., Becho J., Marques J., Roxo J. The prevalence of multiple sclerosis in the District of Santarem, Portugal. J. Neurol. 2006, 253:914-918.
85. De Zélicourt M., Buteau L., Fagnani F., Jallon P. The contributing factors to medical cost of epilepsy: an estimation based on a French prospective cohort study of patients with newly diagnosed epileptic seizures (the CAROLE study). Active coordination of the longitudinal observational network in epilepsy. Seizure 2000, 9:88-95.
86. De Zélicourt M., Dardennes R., Verdoux H., Gandhi G., Khoshnood B., Chomette E., Papatheodorou M.L., Edgell E.T., Even C., Fagnani F. Frequency of hospitalisations and inpatient care costs of manic episodes: in patients with bipolar I disorder in France. PharmacoEconomics 2003, 21:1081-1090.
87. de Girolamo G., Polidori G., Morosini P., Scarpino V., Reda V., Serra G., Mazzi F., Alonso J., Vilagut G., Visona G., Falsirollo F., Rossi A., Warner R. Prevalence of common mental disorders in Italy: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD). Soc. Psychiatry Psychiatr. Epidemiol. 2006, 41:853-861.
88. de Graaf R., Ten Have M., van Gool C., van Dorsselaer S. Prevalence of mental disorders and trends from 1996 to 2009. Results from the Netherlands Mental Health Survey and incidence study-2. Soc. Psychiatry Psychiatr. Epidemiol. 2011, 2011 Jan 1. [Epub ahead of print].
89. Dean G., Elian M., de Bono A.G., Asciak R.P., Vella N., Mifsud V., Aquilina J. Multiple sclerosis in Malta in 1999: an update. J. Neurol. Neurosurg. Psychiatry 2002, 73:256-260.
90. DeAngelis L.M. Brain tumors. N. Engl. J. Med. 2001, 344:114-123.
91. Dengler I., Leukel N., Meuser T., Jost W.H. Prospective study of the direct and indirect costs of idiopathic Parkinson's disease. Nervenarzt 2006, 77:1204-1209.
92. Dikmen S., Machamer J., Temkin N. Psychosocial outcome in patients with moderate to severe head injury: 2-year follow-up. Brain Inj. 1993, 7:113-124.
93. Dikmen S.S., Temkin N.R., Machamer J.E., Holubkov A.L., Fraser R.T., Winn H.R. Employment following traumatic head injuries. Arch. Neurol. 1994, 51:177-186.
94. Dikmen S.S., Ross B.L., Machamer J.E., Temkin N.R. One year psychosocial outcome in head injury. J. Int. Neuropsychol. Soc. 1995, 1:67-77.
95. Dodel R.C., Singer M., Kohne-Volland R., Selzer R., Scholz W., Rathay B., Oertel W.H. Cost of illness in Parkinson disease. A retrospective 3-month analysis of direct costs. Nervenarzt 1997, 68:978-984.
96. Dodel R.C., Singer M., Kohne-Volland R., Szucs T., Rathay B., Scholz E., Oertel W.H. The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis. PharmacoEconomics 1998, 14:299-312.
97. Dominguez M.D., Wichers M., Lieb R., Wittchen H.U., van Os J. Evidence that onset of clinical psychosis is an outcome of progressively more persistent subclinical psychotic experiences: an 8-year cohort study. Schizophr. Bull. 2011, 37:84-93.
98. Döpfner M., Breuer D., Wille N., Erhart M., Ravens-Sieberer U. How often do children meet ICD-10/DSM-IV criteria of attention deficit/hyperactivity disorder and hyperkinetic disorder? Parent-based prevalence rates in a national sample-results of the BELLA study. Eur. Child Adolesc. Psychiatry 2008, 17(Suppl. 1):59-70.
99. Dura-Trave T., Yoldi-Petri M.E., Gallinas-Victoriano F. Incidence of epilepsies and epileptic syndromes among children in Navarre, Spain: 2002 through 2005. J. Child Neurol. 2008, 23:878-882.
100. Durkin M. The epidemiology of developmental disabilities in low-income countries. Ment. Retard. Dev. Disabil. Res. Rev. 2002, 8:206-211.
101. Edwards P., Arango M., Balica L., Cottingham R., El-Sayed H., Farrell B., Fernandes J., Gogichaisvili T., Golden N., Hartzenberg B., Husain M., Ulloa M.I., Jerbi Z., Khamis H., Komolafe E., Laloe V., Lomas G., Ludwig S., Mazairac G., Munoz Sanchez M.L., Nasi L., Olldashi F., Plunkett P., Roberts I., Sandercock P., Shakur H., Soler C., Stocker R., Svoboda P., Trenkler S., Venkataramana N.K., Wasserberg J., Yates D., Yutthakasemsunt S. Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6months. Lancet 2005, 365:1957-1959.
102. Ehret R., Balzer-Geldsetzer M., Reese J.P., Dodel I., Becker E., Christopher A., Friedrich H., Kraemer S., Luer W., Mungersdorf M., Puzich R., Rohr A., Schultes-Platzek I., Siefjediers V., Tiel-Wilck K., Oertel W.H., Dodel R. Direct costs for Parkinson's treatment in private neurology practices in Berlin. Nervenarzt 2009, 80:452-458.
103. Endziniene M., Pauza V., Miseviciene I. Prevalence of childhood epilepsy in Kaunas, Lithuania. Brain Dev. 1997, 19:379-387.
104. Engholm G., Ferlay J., Christensen N., Bray F., Gjerstorff M.L., Klint A., Kotlum J.E., Olafsdottir E., Pukkala E., Storm H.H. NORDCAN-a Nordic tool for cancer information, planning, quality control and research. Acta Oncol. 2010, 49:725-736.
105. Eriksson K.J., Koivikko M.J. Prevalence, classification, and severity of epilepsy and epileptic syndromes in children. Epilepsia 1997, 38:1275-1282.
106. Errea J.M., Ara J.R., Aibar C., De Pedro-Cuesta J. Prevalence of Parkinson's disease in lower Aragon, Spain. Mov. Disord. 1999, 14:596-604.
107. Espèrou H., Jars-Guincestre M.C., Bolgert F., Raphael J.C., Durand-Zaleski I. Cost analysis of plasma-exchange therapy for the treatment of Guillain-Barre syndrome. French Cooperative Group on plasma exchange in Guillain-Barre syndrome. Intensive Care Med. 2000, 26:1094-1100.
108. Esser G., Schmidt M.H., Woerner W. Epidemiology and course of psychiatric disorders in school-age children-results of a longitudinal study. J. Child Psychol. Psychiatry 1990, 31:243-263.
109. European Central Bank Exchange Rates http://sdw.ecb.europa.eu/browse.do?node=2018779.
110. European Commission Brain Research EU Funding 2009, 1-110.
111. European Heart Network Annual Report http://www.ehnheart.org/publications/annual-reports.html.
112. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Statistical Bulletin http://www.emcdda.europa.eu/stats10.
113. European Network for Parkinson's Disease European Network for Parkinson's Disease (EuroPa) http://www.europarkinson.net.
114. Eurostat Average Annual Gross Earnings by Economic Activity - Nace Rev. 1.1 http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=earn_gr_nace&lang=en.
115. Eurostat Average Annual Gross Earnings by Economic Activity - Nace Rev. 2 http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=earn_gr_nace2&lang=en.
116. Eurostat Average Annual Gross Earnings by Occupation http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=earn_gr_isco&lang=en.
117. Eurostat Comparative Price Levels http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=prc_ppp_ind&lang=en.
118. Eurostat Expenditure of Selected Health Care Functions by Providers of Health Care, Per Inhabitant http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=hlth_sha1h&lang=en.
119. Eurostat GDP and Main Components - Current Prices http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=nama_gdp_c&lang=en.
120. Eurostat Harmonised Annual Average Consumer Price Indices http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=prc_hicp_aind&lang=en.
121. Eurostat Labour Cost Index, Nominal Value - Annual Data http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=lc_lci_r1_a&lang=en.
122. Eurostat Monthly Labour Costs http://epp.eurostat.ec.europa.eu/tgm/table.do?tab=table&init=1&plugin=1&language=en&pcode=tps00174.
123. Eurostat Population on 1 January by Age and Sex http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=demo_pjan&lang=en.
124. Evers S.M., Struijs J.N., Ament A.J., van Genugten M.L., Jager J.H., van den Bos G.A. International comparison of stroke cost studies. Stroke 2004, 35:1209-1215.
125. Fasbender P., Kölmel H.W. Incidence of multiple sclerosis in the urban area of Erfurt, Thuringia, Germany. Neuroepidemiology 2008, 30:147-151.
126. Fenoglio P., Parel V., Kopp P. The social cost of alcohol, tobacco and illicit drugs in France, 1997. Eur. Addict. Res. 2003, 9:18-28.
127. Ferini-Strambi L., Zucconi M., Palazzi S., Castronovo V., Oldani A., Della M.G., Smirne S. Snoring and nocturnal oxygen desaturations in an Italian middle-aged male population. Epidemiologic study with an ambulatory device. Chest 1994, 105:1759-1764.
128. Ferini-Strambi L., Zucconi M., Castronovo V., Garancini P., Oldani A., Smirne S. Snoring & sleep apnea: a population study in Italian women. Sleep 1999, 22:859-864.
129. Ferlay J., Parkin D.M., Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 2010, 46:765-781.
130. Florescu S., Moldovan M., Mihaescu-Pintia C., Ciutan M., Sorel G.E. The Mental Health Study. Romania 2007. Prevalence, severity, and treatment of 12-month DSM-IV disorders. Manage. Health 2009, 13:23-31.
131. Fombonne E. Epidemiology of pervasive developmental disorders. Pediatr. Res. 2009, 65:591-598.
132. Ford T., Goodman R., Meltzer H. The British Child and Adolescent Mental Health Survey 1999: the prevalence of DSM-IV disorders. J. Am. Acad. Child Adolesc. Psychiatry 2003, 42:1203-1211.
133. Forsgren L. Prevalence of epilepsy in adults in northern Sweden. Epilepsia 1992, 33:450-458.
134. Forsgren I., Beghi E., Ekman M. Cost of epilepsy in Europe. Eur. J. Neurol. 2005, 12(Suppl. 1):54-58.
135. Forsgren L., Beghi E., Õun A., SillanpÃ{currency sign}Ã{currency sign} M. The epidemiology of epilepsy in Europe - a systematic review. Eur. J. Neurol. 2005, 12:245-253.
136. Framework Programme 6 http://ec.europa.eu/research/health/medical-research/pdf/brain-research-eu-funding-2002-2009_en.pdf.
137. Francois C., Sintonen H., Sulkava R., Rive B. Cost effectiveness of memantine in moderately severe to severe Alzheimer's disease: a Markov model in Finland. Clin. Drug Investig. 2004, 24:373-384.
138. Friemel S., Bernert S., Angermeyer M.C., Konig H.H. The direct costs of depressive disorders in Germany. Psychiatr. Prax. 2005, 32:113-121.
139. Fromont A., Binquet C., Sauleau E.A., Fournel I., Bellisario A., Adnet J., Weill A., Vukusic S., Confavreux C., Debouverie M., Clerc L., Bonithon-Kopp C., Moreau T. Geographic variations of multiple sclerosis in France. Brain 2010, 133:1889-1899.
140. Gallitto G., Serra S., La Spina P., Postorino P., Lagana A., Tripodi F., Gangemi S., Calabro S., Savica R., Di Perri R., Beghi E., Musolino R. Prevalence and characteristics of epilepsy in the Aeolian islands. Epilepsia 2005, 46:1828-1835.
141. Gao S., Juhaeri J., Dai W.S. The incidence rate of seizures in relation to BMI in UK adults. Obesity (Silver Spring) 2008, 16:2126-2132.
142. Garattini L., Barbui C., Clemente R., Cornago D., Parazzini F. Direct costs of schizophrenia and related disorders in Italian community mental health services: a multicenter, prospective 1-year followup study. Schizophr. Bull. 2004, 30:295-302.
143. Garcia-Altes A., Olle J.M., Antonanzas F., Colom J. The social cost of illegal drug consumption in Spain. Addiction 2002, 97:1145-1153.
144. Gascon-Bayarri J., Rene R., Del Barrio J.L., De Pedro-Cuesta J., Ramon J.M., Manubens J.M., Sanchez C., Hernandez M., Estela J., Juncadella M., Rubio F.R. Prevalence of dementia subtypes in El Prat de Llobregat, Catalonia, Spain: the PRATICON study. Neuroepidemiology 2007, 28:224-234.
145. Gerzeli S., Tarricone R., Zolo P., Colangelo I., Busca M.R., Gandolfo C. The economic burden of stroke in Italy. The EcLIPSE study: economic longitudinal incidence-based project for stroke evaluation. Neurol. Sci. 2005, 26:72-80.
146. Gessner U., Sagmeister M., Horisberger B. The cost of epilepsy in Switzerland. Int. J. Health Sci. 1993, 4:121-128.
147. Gislason T., Almqvist M., Eriksson G., Taube A., Boman G. Prevalence of sleep apnea syndrome among Swedish men-an epidemiological study. J. Clin. Epidemiol. 1988, 41:571-576.
148. Giuliani G., Terziani S., Senigaglia A.R., Luccioni G., Foschi N., Maffei C. Epilepsy in an Italian community as assessed by a survey for prescriptions of antiepileptic drugs: epidemiology and patterns of care. Acta Neurol. Scand. 1992, 85:23-31.
149. Godet-Cayré V., Pelletier-Fleury N., Le V.M., Dinet J., Massuel M.A., Leger D. Insomnia and absenteeism at work. Who pays the cost?. Sleep 2006, 29:179-184.
150. Godfrey C., Stewart D., Gossop M. Economic analysis of costs and consequences of the treatment of drug misuse: 2-year outcome data from the National Treatment Outcome Research Study (NTORS). Addiction 2004, 99:697-707.
151. Goldberg L.D. The cost of migraine and its treatment. Am. J. Manag. Care. 2005, 11:S62-S67.
152. Gomez-Beneyto M., Bonet A., Catala M.A., Puche E., Vila V. Prevalence of mental disorders among children in Valencia, Spain. Acta Psychiatr. Scand. 1994, 89:352-357.
153. Gonzalez-Pinto A.M., Dardennes R., de Zélicourt M., Lopez P., Oliveros R.G., Vieta E., Barbeito S., Echevarria E., Fagnani F. In-patient care costs of patients with bipolar I disorder: a comparison between two European centers. J. Affect. Disord. 2010, 121:152-155.
154. Gostynski M., Ajdacic-Gross V., Gutzwiller F., Michel J.P., Herrmann F. Prevalence of dementia in the city of Zurich. Soz. Praventivmed. 2002, 47:330-335.
155. Grabe H.J., Baumeister S.E., John U., Freyberger H.J., Volzke H. Association of mental distress with health care utilization and costs: a 5-year observation in a general population. Soc. Psychiatry Psychiatr. Epidemiol. 2009, 44:835-844.
156. Granieri E., Rosati G., Tola R., Pavoni M., Paolino E., Pinna L., Monetti V.C. A descriptive study of epilepsy in the district of Copparo, Italy, 1964-1978. Epilepsia 1983, 24:502-514.
157. Granieri E., Economou N.T., De G.R., Tola M.R., Caniatti L., Govoni V., Fainardi E., Casetta I. Multiple sclerosis in the province of Ferrara: evidence for an increasing trend. J. Neurol. 2007, 254:1642-1648.
158. Gray O.M., McDonnell G.V., Hawkins S.A. Factors in the rising prevalence of multiple sclerosis in the north-east of Ireland. Mult. Scler. 2008, 14:880-886.
159. Guerrini R., Battini R., Ferrari A.R., Veggiotti P., Besana D., Gobbi G., Pezzani M., Berta E., Tetto A., Beghi E., Monticelli M.L., Tediosi F., Garattini L., Russo S., Rasmini P., Amadi A., Quarti P., Fabrizzi R. The costs of childhood epilepsy in Italy: comparative findings from three health care settings. Epilepsia 2001, 42:641-646.
160. Guglieri M., Straub V., Bushby K., Lochmuller H. Limb-girdle muscular dystrophies. Curr. Opin. Neurol. 2008, 21:576-584.
161. Gustavsson A., Jonsson L., Rapp T., Reynish E., Ousset P.J., Andrieu S., Cantet C., Winblad B., Vellas B., Wimo A. Differences in resource use and costs of dementia care between European countries: baseline data from the ICTUS study. J. Nutr. Health Aging 2010, 14:648-654.
162. Gustavsson A., Brinck P., Bergvall N., Kolasa K., Wimo A., Winblad B., Jonsson L. Predictors of costs of care in Alzheimer's disease: a multinational sample of 1222 patients. Alzheimers Dement. 2011, 7:318-327.
163. Hagell P., Nordling S., Reimer J., Grabowski M., Persson U. Resource use and costs in a Swedish cohort of patients with Parkinson's disease. Mov. Disord. 2002, 17:1213-1220.
164. Hakkaart-van Roijen L., Hoeijenbos M.B., Regeer E.J., Ten Have M., Nolen W.A., Veraart C.P., Rutten F.F. The societal costs and quality of life of patients suffering from bipolar disorder in the Netherlands. Acta Psychiatr. Scand. 2004, 110:383-392.
165. Hakkaart-van R.L., Zwirs B.W., Bouwmans C., Tan S.S., Schulpen T.W., Vlasveld L., Buitelaar J.K. Societal costs and quality of life of children suffering from attention deficient hyperactivity disorder (ADHD). Eur. Child Adolesc. Psychiatry 2007, 16:316-326.
166. Halpin D.M. Health economics of chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2006, 3:227-233.
167. Hamer H.M., Spottke A., Aletsee C., Knake S., Reis J., Strzelczyk A., Oertel W.H., Rosenow F., Dodel R. Direct and indirect costs of refractory epilepsy in a tertiary epilepsy center in Germany. Epilepsia 2006, 47:2165-2172.
168. Hamre H.J., Glockmann A., Troger W., Kienle G.S., Kiene H. Assessing the order of magnitude of outcomes in single-arm cohorts through systematic comparison with corresponding cohorts: an example from the AMOS study. BMC Med. Res. Methodol. 2008, 8:11.
169. Hansen A.B., Hvidtfeldt U.A., Gronbaek M., Becker U., Nielsen A.S., Tolstrup J.S. The number of persons with alcohol problems in the Danish population. Scand. J. Public Health 2011, 39:128-136.
170. Hausken A.M., Furu K., Skurtveit S., Engeland A., Bramness J.G. Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database study of predictors. Eur. J. Clin. Pharmacol. 2009, 65:295-301.
171. Healey A., Knapp M., Astin J., Gossop M., Marsden J., Stewart D., Lehmann P., Godfrey C. Economic burden of drug dependency. Social costs incurred by drug users at intake to the National Treatment Outcome Research Study. Br. J. Psychiatry 1998, 173:160-165.
172. Hedner J., Bengtsson-Bostrom K., Peker Y., Grote L., Rastam L., Lindblad U. Hypertension prevalence in obstructive sleep apnoea and sex: a population-based case-control study. Eur. Respir. J. 2006, 27:564-570.
173. Heider D., Bernert S., Konig H.H., Matschinger H., Hogh T., Brugha T.S., Bebbington P.E., Azorin M., Angermeyer M.C., Toumi M. Direct medical mental health care costs of schizophrenia in France, Germany and the United Kingdom - findings from the European Schizophrenia Cohort (EuroSC). Eur. Psychiatry 2009, 24:216-224.
174. Heier M.S., Evsiukova T., Wilson J., Abdelnoor M., Hublin C., Ervik S. Prevalence of narcolepsy with cataplexy in Norway. Acta Neurol. Scand. 2009, 120:276-280.
175. Helmer C., Peres K., Letenneur L., Guttierez-Robledo L.M., Ramaroson H., Barberger-Gateau P., Fabrigoule C., Orgogozo J.M., Dartigues J.F. Dementia in subjects aged 75years or over within the PAQUID cohort: prevalence and burden by severity. Dement. Geriatr. Cogn. Disord. 2006, 22:87-94.
176. Hetta J., Broman J.E., Mallon L. Evaluation of severe insomnia in the general population-implications for the management of insomnia: insomnia, quality of life and healthcare consumption in Sweden. J. Psychopharmacol. 1999, 13:S35-S36.
177. Hiller W., Fichter M.M. High utilizers of medical care: a crucial subgroup among somatizing patients. J. Psychosom. Res. 2004, 56:437-443.
178. Hirst C., Ingram G., Pickersgill T., Swingler R., Compston D.A., Robertson N.P. Increasing prevalence and incidence of multiple sclerosis in South East Wales. J. Neurol. Neurosurg. Psychiatry 2009, 80:386-391.
179. Hodgson T.A., Meiners M.R. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem. Fund Q. Health Soc. 1982, 60:429-462.
180. Hoflstein V. Relationship between smoking and sleep apnea in clinic population. Sleep 2002, 25:519-524.
181. Hong S.C., Leen K., Park S.A., Han J.H., Lee S.P., Lin L., Okun M., Nishino S., Mignot E. HLA and hypocretin studies in Korean patients with narcolepsy. Sleep 2002, 25:440-444.
182. Hong J., Windmeijer F., Novick D., Haro J.M., Brown J. The cost of relapse in patients with schizophrenia in the European SOHO (Schizophrenia Outpatient Health Outcomes) study. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:835-841.
183. Hossain J.L., Shapiro C.M. The prevalence, cost implications, and management of sleep disorders: an overview. Sleep Breath. 2002, 6:85-102.
184. Hublin C., Kaprio J., Partinen M., Koskenvuo M., Heikkila K., Koskimies S., Guilleminault C. The prevalence of narcolepsy: an epidemiological study of the Finnish Twin Cohort. Ann. Neurol. 1994, 35:709-716.
185. Hublin C., Partinen M., Kaprio J., Koskenvuo M., Guilleminault C. Epidemiology of narcolepsy. Sleep 1994, 17:S7-S12.
186. Huisman M.H., de Jong S.W., van Doormaal P.T., Weinreich S.S., Schelhaas H.J., van der Kooi A.J., de Visser M., Veldink J.H., van den Berg L.H. Population based epidemiology of amyotrophic lateral sclerosis using capture-recapture methodology. J. Neurol. Neurosurg. Psychiatry 2011, 2011 May 27 [Electronic publication ahead of print].
187. Human Mortality Database, 2010. United Kingdom, Life tables (period 1x1), Total.
188. Iuliano G., Napoletano R. Prevalence and incidence of multiple sclerosis in Salerno (southern Italy) and its province. Eur. J. Neurol. 2008, 15:73-76.
189. Jacobi F., Wittchen H.U., Holting C., Sommer S., Lieb R., Hofler M., Pfister H. Estimating the prevalence of mental and somatic disorders in the community: aims and methods of the German National Health Interview and Examination Survey. Int. J. Methods Psychiatr. Res. 2002, 11:1-18.
190. Jacobi F., Wittchen H.U., Holting C., Hofler M., Pfister H., Muller N., Lieb R. Prevalence, co-morbidity and correlates of mental disorders in the general population: results from the German Health Interview and Examination Survey (GHS). Psychol. Med. 2004, 34:597-611.
191. Jacoby A., Buck D., Baker G., McNamee P., Graham-Jones S., Chadwick D. Uptake and costs of care for epilepsy: findings from a U.K. regional study. Epilepsia 1998, 39:776-786.
192. Jansson-Frojmark M., Linton S.J. The course of insomnia over one year: a longitudinal study in the general population in Sweden. Sleep 2008, 31:881-886.
193. Järbrink K. The economic consequences of autistic spectrum disorder among children in a Swedish municipality. Autism 2007, 11:453-463.
194. Jarl J., Johansson P., Eriksson A., Eriksson M., Gerdtham U.G., Hemstrom O., Selin K.H., Lenke L., Ramstedt M., Room R. The societal cost of alcohol consumption: an estimation of the economic and human cost including health effects in Sweden, 2002. Eur. J. Health Econ. 2008, 9:351-360.
195. Jennum P., Kjellberg J. The socio-economical burden of hypersomnia. Acta Neurol. Scand. 2010, 121:265-270.
196. Jennum P., Kjellberg J. Health, social and economical consequences of sleep-disordered breathing: a controlled national study. Thorax 2011, 66:560-566.
197. Jennum P., Riha R.L. Epidemiology of sleep apnoea/hypopnoea syndrome and sleep-disordered breathing. Eur. Respir. J. 2009, 33:907-914.
198. Jennum P., Sjol A. Snoring, sleep apnoea and cardiovascular risk factors: the MONICA II study. Int. J. Epidemiol. 1993, 22:439-444.
199. Jennum P., Sjol A. Self-assessed cognitive function in snorers and sleep apneics. An epidemiological study of 1504 females and males aged 30-60years: the Dan-MONICA II study. Eur. Neurol. 1994, 34:204-208.
200. Jennum P., Knudsen S., Kjellberg J. The economic consequences of narcolepsy. J. Clin. Sleep Med. 2009, 5:240-245.
201. Joensen P. Prevalence, incidence, and classification of epilepsy in the Faroes. Acta Neurol. Scand. 1986, 74:150-155.
202. Jonsson B. Revealing the cost of type II diabetes in Europe. Diabetologia 2002, 45:S5-S12.
203. Jönsson L., Berr C. Cost of dementia in Europe. Eur. J. Neurol. 2005, 12(Suppl. 1):50-53.
204. Jönsson L., Lindgren P., Wimo A., Jönsson B., Winblad B. The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model. Clin. Ther. 1999, 21:1230-1240.
205. Jönsson L., Eriksdotter J.M., Kilander L., Soininen H., Hallikainen M., Waldemar G., Nygaard H., Andreasen N., Winblad B., Wimo A. Determinants of costs of care for patients with Alzheimer's disease. Int. J. Geriatr. Psychiatry 2006, 21:449-459.
206. Kalb B., Matell G., Pirskanen R., Lambe M. Epidemiology of myasthenia gravis: a population-based study in Stockholm, Sweden. Neuroepidemiology 2002, 21:221-225.
207. Keller S., Kessler T., Meuser T., Fogel W., Bremen D., Jost W.H. Analysis of direct costs in therapy of Parkinson disease. Nervenarzt 2003, 74:1105-1109.
208. Keränen T., Riekkinen P.J., Sillanpää M. Incidence and prevalence of epilepsy in adults in eastern Finland. Epilepsia 1989, 30:413-421.
209. Keränen T., Kaakkola S., Sotaniemi K., Laulumaa V., Haapaniemi T., Jolma T., Kola H., Ylikoski A., Satomaa O., Kovanen J., Taimela E., Haapaniemi H., Turunen H., Takala A. Economic burden and quality of life impairment increase with severity of PD. Parkinsonism Relat. Disord. 2003, 9:163-168.
210. King B.H., Toth K.E., Hodapp R.M., Dykens E.M. Intellectual disability. Comprehensive Textbook of Psychiatry 2009, 3444-3474. B.J. Sadock, V.A. Sadock, P. Ruiz (Eds.).
211. Kleinman L., Lowin A., Flood E., Gandhi G., Edgell E., Revicki D. Costs of bipolar disorder. PharmacoEconomics 2003, 21:601-622.
212. Knapp M., Chisholm D., Leese M., Amaddeo F., Tansella M., Schene A., Thornicroft G., Vazquez-Barquero J.L., Knudsen H.C., Becker T. Comparing patterns and costs of schizophrenia care in five European countries: the EPSILON study. European Psychiatric Services: inputs linked to outcome domains and needs. Acta Psychiatr. Scand. 2002, 105:42-54.
213. Knapp M., Mangalore R., Simon J. The global costs of schizophrenia. Schizophr. Bull. 2004, 30:279-293.
214. Knapp M., Romeo R., Beecham J. Economic cost of autism in the UK. Autism 2009, 13:317-336.
215. Kobelt G. Costs and quality of life for patients with multiple sclerosis in Belgium. Eur. J. Health Econ. 2006, 7(Suppl. 2):S24-S33.
216. Kobelt G., Kasteng F. Access to Innovative Treatments in Multiple Sclerosis in Europe http://www.comparatorreports.se/Access%20to%20MS%20treatments%20-%20October%202009.pdf.
217. Kobelt G., Berg J., Lindgren P., Anten B., Ekman M., Jongen P.J., Polman C., Uitdehaag B. Costs and quality of life in multiple sclerosis in The Netherlands. Eur. J. Health Econ. 2006, 7(Suppl. 2):S55-S64.
218. Kobelt G., Berg J., Lindgren P., Battaglia M., Lucioni C., Uccelli A. Costs and quality of life of multiple sclerosis in Italy. Eur. J. Health Econ. 2006, 7(Suppl. 2):S45-S54.
219. Kobelt G., Berg J., Lindgren P., Elias W.G., Flachenecker P., Freidel M., Konig N., Limmroth V., Straube E. Costs and quality of life of multiple sclerosis in Germany. Eur. J. Health Econ. 2006, 7(Suppl. 2):S34-S44.
220. Kobelt G., Berg J., Lindgren P., Gerfin A., Lutz J. Costs and quality of life of multiple sclerosis in Switzerland. Eur. J. Health Econ. 2006, 7(Suppl. 2):S86-S95.
221. Kobelt G., Berg J., Lindgren P., Izquierdo G., Sanchez-Solino O., Perez-Miranda J., Casado M.A. Costs and quality of life of multiple sclerosis in Spain. Eur. J. Health Econ. 2006, 7(Suppl. 2):S65-S74.
222. Kobelt G., Berg J., Lindgren P., Kerrigan J., Russell N., Nixon R. Costs and quality of life of multiple sclerosis in the United Kingdom. Eur. J. Health Econ. 2006, 7(Suppl. 2):S96-S104.
223. Kobelt G., Berg J., Lindgren P., Plesnilla C., Baumhackl U., Berger T., Kolleger H., Vass K. Costs and quality of life of multiple sclerosis in Austria. Eur. J. Health Econ. 2006, 7(Suppl. 2):S14-S23.
224. Kobelt G., Texier-Richard B., Lindgren P. The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions. Mult. Scler. 2009, 15:741-751.
225. Kobelt G., Miltenburger C., Gunther O., Justo N., Karampampa K., Texier-Richard B., Schweickert B. A survey of barriers to treatment access in reumatoid arthritis in France, Germany, Italy, Spain and the UK http://www.comparatorreports.se/RA%20Barrier%20Report_FINAL_050110.pdf.
226. Kolominsky-Rabas P.L., Heuschmann P.U., Marschall D., Emmert M., Baltzer N., Neundorfer B., Schoffski O., Krobot K.J. Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen Stroke Project. Stroke 2006, 37:1179-1183.
227. Konnopka A., Konig H.H. Direct and indirect costs attributable to alcohol consumption in Germany. PharmacoEconomics 2007, 25:605-618.
228. Kotsopoulos I.A., Evers S.M., Ament A.J., de Krom M.C. Estimating the costs of epilepsy: an international comparison of epilepsy cost studies. Epilepsia 2001, 42:634-640.
229. Kotsopoulos I.A., Evers S.M., Ament A.J., Kessels F.G., de Krom M.C., Twellaar M., Metsemakers J.F., Knottnerus A.J. The costs of epilepsy in three different populations of patients with epilepsy. Epilepsy Res. 2003, 54:131-140.
230. Kotsopoulos I., de Krom M., Kessels F., Lodder J., Troost J., Twellaar M., van Merode T., Knottnerus A. Incidence of epilepsy and predictive factors of epileptic and non-epileptic seizures. Seizure 2005, 14:175-182.
231. Krauth C., Buser K., Vogel H. How high are the costs of eating disorders - anorexia nervosa and bulimia nervosa - for German society?. Eur. J. Health Econ. 2002, 3:244-250.
232. Kroes M., Kalff A.C., Kessels A.G., Steyaert J., Feron F.J., van Someren A.J., Hurks P.P., Hendriksen J.G., van Zeben T.M., Rozendaal N., Crolla I.F., Troost J., Jolles J., Vles J.S. Child psychiatric diagnoses in a population of Dutch schoolchildren aged 6 to 8years. J. Am. Acad. Child Adolesc. Psychiatry 2001, 40:1401-1409.
233. Kronborg A.C., Sogaard J., Hansen E., Kragh-Sorensen A., Hastrup L., Andersen J., Andersen K., Lolk A., Nielsen H., Kragh-Sorensen P. The cost of dementia in Denmark: the Odense study. Dement. Geriatr. Cogn. Disord. 1999, 10:295-304.
234. Kronholm E., Partonen T., Laatikainen T., Peltonen M., Harma M., Hublin C., Kaprio J., Aro A.R., Partinen M., Fogelholm M., Valve R., Vahtera J., Oksanen T., Kivimaki M., Koskenvuo M., Sutela H. Trends in self-reported sleep duration and insomnia-related symptoms in Finland from 1972 to 2005: a comparative review and re-analysis of Finnish population samples. J. Sleep Res. 2008, 17:54-62.
235. Kryger M.H., Walid R., Manfreda J. Diagnoses received by narcolepsy patients in the year prior to diagnosis by a sleep specialist. Sleep 2002, 25:36-41.
236. Kurz X., Scuvee-Moreau J., Salmon E., Pepin J.L., Ventura M., Dresse A. Dementia in Belgium: prevalence in aged patients consulting in general practice. Rev. Med. Liege 2001, 56:835-839.
237. Laaban J.P., Daenen S., Leger D., Pascal S., Bayon V., Slama G., Elgrably F. Prevalence and predictive factors of sleep apnoea syndrome in type 2 diabetic patients. Diabetes Metab. 2009, 35:372-377.
238. Landgren M., Pettersson R., Kjellman B., Gillberg C. ADHD, DAMP and other neurodevelopmental/psychiatric disorders in 6-year-old children: epidemiology and co-morbidity. Dev. Med. Child Neurol. 1996, 38:891-906.
239. Larsson K., Eeg-Olofsson O. A population based study of epilepsy in children from a Swedish county. Eur. J. Paediatr. Neurol. 2006, 10:107-113.
240. Latif A.Z., Signorini D., Gregor A., Whittle I.R. The costs of managing patients with malignant glioma at a neuro-oncology clinic. Br. J. Neurosurg. 1998, 12:118-122.
241. Latvala A., Tuulio-Henriksson A., Perala J., Saarni S.I., Aalto-Setala T., Aro H., Korhonen T., Koskinen S., Lonnqvist J., Kaprio J., Suvisaari J. Prevalence and correlates of alcohol and other substance use disorders in young adulthood: a population-based study. BMC Psychiatry 2009, 9:73.
242. Lauber C., Keller C., Eichenberger A., Rossler W. Family burden during exacerbation of schizophrenia: quantification and determinants of additional costs. Int. J. Soc. Psychiatry 2005, 51:259-264.
243. LeBlanc M., Merette C., Savard J., Ivers H., Baillargeon L., Morin C.M. Incidence and risk factors of insomnia in a population-based sample. Sleep 2009, 32:1027-1037.
244. Leger D., Poursain B. An international survey of insomnia: under-recognition and under-treatment of a polysymptomatic condition. Curr. Med. Res. Opin. 2005, 21:1785-1792.
245. Leger D., Levy E., Paillard M. The direct costs of insomnia in France. Sleep 1999, 22(Suppl. 2):S394-S401.
246. Leger D., Guilleminault C., Dreyfus J.P., Delahaye C., Paillard M. Prevalence of insomnia in a survey of 12,778 adults in France. J. Sleep Res. 2000, 9:35-42.
247. Leger D., Massuel M.A., Metlaine A. Professional correlates of insomnia. Sleep 2006, 29:171-178.
248. LePen C., Wait S., Moutard-Martin F., Dujardin M., Ziegler M. Cost of illness and disease severity in a cohort of French patients with Parkinson's disease. PharmacoEconomics 1999, 16:59-69.
249. Lépine J.P. The epidemiology of anxiety disorders: prevalence and societal costs. J. Clin. Psychiatry 2002, 63(Suppl. 14):4-8.
250. Li X., Sundquist K., Sundquist J. Socioeconomic status and occupation as risk factors for obstructive sleep apnea in Sweden: a population-based study. Sleep Med. 2008, 9:129-136.
251. Lindberg E., Berne C., Franklin K.A., Svensson M., Janson C. Snoring and daytime sleepiness as risk factors for hypertension and diabetes in women-a population-based study. Respir. Med. 2007, 101:1283-1290.
252. Linde, M., Gustavsson, A., Stovner, L.J., Barré, J., Katsarava, Z., Lainez, J,M., Lampl, C., Lantéri-Minet, M., Rastenyte, D., Ruiz de la Torre, E., Steiner, T.J., Tassorelli, C., Andrée, C., 2011. The cost of headache disorders in Europe - the Eurolight project. Manuscript.
253. Lindgren P., von Campenhausen S., Spottke E., Siebert U., Dodel R. Cost of Parkinson's disease in Europe. Eur. J. Neurol. 2005, 12(Suppl. 1):68-73.
254. Lindström E., Eberhard J., Neovius M., Levander S. Costs of schizophrenia during 5years. Acta Psychiatr. Scand. Suppl. 2007, 33-40.
255. Linehan C., Kerr M.P., Walsh P.N., Brady G., Kelleher C., Delanty N., Dawson F., Glynn M. Examining the prevalence of epilepsy and delivery of epilepsy care in Ireland. Epilepsia 2010, 51:845-852.
256. Livingston G., Katona C., Roch B., Guilhaume C., Rive B. A dependency model for patients with Alzheimer's disease: its validation and relationship to the costs of care-the LASER-AD study. Curr. Med. Res. Opin. 2004, 20:1007-1016.
257. Löfgren E., Pouta A., von Wendt L., Tapanainen J., IsojÃ{currency sign}rvi J.I., JÃ{currency sign}rvelin M.R. Epilepsy in the northern Finland birth cohort 1966 with special reference to fertility. Epilepsy Behav. 2009, 14:102-107.
258. Lopez-Bastida J., Serrano-Aguilar P., Perestelo-Perez L., Oliva-Moreno J. Social-economic costs and quality of life of Alzheimer disease in the Canary Islands, Spain. Neurology 2006, 67:2186-2191.
259. Loredo J.S., Soler X., Bardwell W., Ancoli-Israel S., Dimsdale J.E., Palinkas L.A. Sleep health in U.S. Hispanic population. Sleep 2010, 33:962-967.
260. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., Scheithauer B.W., Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114:97-109.
261. Luengo A., Parra J., Colas J., Ramos F., Carreras T., Fernandez-Pozos M.J., Munoz A., Hernando V. Prevalence of epilepsy in northeast Madrid. J. Neurol. 2001, 248:762-767.
262. Luengo-Fernandez R., Gray A.M., Rothwell P.M. Costs of stroke using patient-level data: a critical review of the literature. Stroke 2009, 40:e18-e23.
263. Mahdi-Rogers M., Al-Chalabi A., Hughes R.A. Epidemiology and treatment of chronic inflammatory neuropathies in South East England. Eur. J. Neurol. 2008, 15(Suppl. 3).
264. Mahdi-Rogers M., Al-Chalabi A., Hughes R.A. Prevalence and morbidity of chronic inflammatory neuropathies in South East England. J. Peripher. Nerv. Syst. 2008, 13(Suppl. 2).
265. Mahdi-Rogers M., Kazmi M., Ferner R., Hughes R.A., Renaud S., Steck A.J., Fuhr P., Halter J., Gratwohl A., Tyndall A. Autologous peripheral blood stem cell transplantation for chronic acquired demyelinating neuropathy. J. Peripher. Nerv. Syst. 2009, 14:118-124.
266. Mahler M.P., Zuger K., Kaspar K., Haefeli A., Jenni W., Leniger T., Beer J.H. A cost analysis of the first year after stroke - early triage and inpatient rehabilitation may reduce long term costs. Swiss. Med. Wkly. 2008, 138:459-465.
267. Malcienë, L., Pauza, V., 2003. I{cu{Eth}sëtinës sklerozës klinikos ir epidemiologijos ypatumai Kauno mieste. 218, 66-69.
268. Mangalore R., Knapp M. Cost of schizophrenia in England. J. Ment. Health Policy Econ. 2007, 10:23-41.
269. Maremmani C., Rossi G., Bonuccelli U., Murri L. Descriptive epidemiologic study of epilepsy syndromes in a district of northwest Tuscany, Italy. Epilepsia 1991, 32:294-298.
270. Martikainen K., Partinen M., Hasan J., Laippala P., Urponen H., Vuori I. The impact of somatic health problems on insomnia in middle age. Sleep Med. 2003, 4:201-206.
271. Martinez-Leal R., Salvador-Carulla L., Linehan C., Walsh P., Weber G., Van H.G., Maatta T., Azema B., Haveman M., Buono S., Germanavicius A., van Schrojenstein Lantman-de Valk, Tossebro J., Carmen-Cara A., Moravec B.D., Perry J., Kerr M. The impact of living arrangements and deinstitutionalisation in the health status of persons with intellectual disability in Europe. J. Intellect. Disabil. Res. 2011, 55(9):858-872. 10.1111/j.1365-2788.291.01439.x.
272. Maulik P.K., Mascarenhas M.N., Mathers C.D., Dua T., Saxena S. Prevalence of intellectual disability: a meta-analysis of population-based studies. Res. Dev. Disabil. 2011, 32:419-436.
273. Maurel F., Lilliu H., Le P.C. Social and economic cost of l-dopa-induced dyskinesias in patients with Parkinson's disease. Rev. Neurol. (Paris) 2001, 157:507-514.
274. McCracken C., Dalgard O.S., Ayuso-Mateos J.L., Casey P., Wilkinson G., Lehtinen V., Dowrick C. Health service use by adults with depression: community survey in five European countries. Evidence from the ODIN study. Br. J. Psychiatry 2006, 189:161-167.
275. McCrone P., Knapp M., Fombonne E. The Maudsley long-term follow-up of child and adolescent depression. Predicting costs in adulthood. Eur. Child Adolesc. Psychiatry 2005, 14:407-413.
276. McCrone P., Allcock L.M., Burn D.J. Predicting the cost of Parkinson's disease. Mov. Disord. 2007, 22:804-812.
277. McCrone P., Heslin M., Knapp M., Bull P., Thompson A. Multiple sclerosis in the UK: service use, costs, quality of life and disability. PharmacoEconomics 2008, 26:847-860.
278. McEvoy J.P. The costs of schizophrenia. J. Clin. Psychiatry 2007, 68(Suppl. 14):4-7.
279. McGrogan A., Madle G.C., Seaman H.E., de Vries C.S. The epidemiology of Guillain-Barre syndrome worldwide. A systematic literature review. Neuroepidemiology 2009, 32:150-163.
280. McNicholas W.T. Sleep apnoea in the British Isles. Lancet 1986, 2:295.
281. Meerding W.J., Mulder S., van Beeck E.F. Incidence and costs of injuries in The Netherlands. Eur. J. Public Health 2006, 16:272-278.
282. Mesterton J., Wimo A., By A., Langworth S., Winblad B., Jonsson L. Cross sectional observational study on the societal costs of Alzheimer's disease. Curr. Alzheimer Res. 2010, 7:358-367.
283. Morgante L., Rocca W.A., Di Rosa A.E., De D.P., Grigoletto F., Meneghini F., Reggio A., Savettieri G., Castiglione M.G., Patti F. Prevalence of Parkinson's disease and other types of parkinsonism: a door-to-door survey in three Sicilian municipalities. The Sicilian Neuro-Epidemiologic Study (SNES) Group. Neurology 1992, 42:1901-1907.
284. Morris S., Ridley S., Lecky F.E., Munro V., Christensen M.C. Determinants of hospital costs associated with traumatic brain injury in England and Wales. Anaesthesia 2008, 63:499-508.
285. Neven A.K., Middelkoop H.A., Kemp B., Kamphuisen H.A., Springer M.P. The prevalence of clinically significant sleep apnoea syndrome in The Netherlands. Thorax 1998, 53:638-642.
286. Norlund A., Marke L.A., af Geijerstam J.L., Oredsson S., Britton M. Immediate computed tomography or admission for observation after mild head injury: cost comparison in randomised controlled trial. BMJ 2006, 333:469.
287. Norwood F.L., Harling C., Chinnery P.F., Eagle M., Bushby K., Straub V. Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain 2009, 132:3175-3186.
288. Nutt D., Goodwin G. ECNP Summit on the future of CNS drug research in Europe 2011: report prepared for ECNP by David Nutt and Guy Goodwin. Eur. Neuropsychopharmacol. 2011, 21:495-499.
289. Annual Income OECD statistics. http://stats.oecd.org.
290. OECD statistics National Accounts - PPPs and exchange rates http://stats.oecd.org/.
291. Total Health Expenditure per Country and Year OECD statistics. http://stats.oecd.org/index.aspx?DataSetCode=HEALTH_STAT.
292. Total Pharmaceutical Expediture OECD statistics. http://www.oecd-ilibrary.org/social-issues-migration-health/health-at-a-glance-europe-2010/pharmaceutical-expenditure_9789264090316-45-en.
293. Office of National Statistics (ONC) Statistical Bulletin 2009: Annual Survey for Hours and Earnings http://www.statistics.gov.uk/pdfdir/ashe1109.pdf.
294. Ohayon M.M., Partinen M. Insomnia and global sleep dissatisfaction in Finland. J. Sleep Res. 2002, 11:339-346.
295. Ohayon M.M., Guilleminault C., Priest R.G., Caulet M. Snoring and breathing pauses during sleep: telephone interview survey of a United Kingdom population sample. BMJ 1997, 314:860-863.
296. Ohayon M.M., Priest R.G., Zulley J., Smirne S., Paiva T. Prevalence of narcolepsy symptomatology and diagnosis in the European general population. Neurology 2002, 58:1826-1833.
297. Olafsson E., Hauser W.A. Prevalence of epilepsy in rural Iceland: a population-based study. Epilepsia 1999, 40:1529-1534.
298. Olafsson E., Ludvigsson P., Gudmundsson G., Hesdorffer D., Kjartansson O., Hauser W.A. Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification: a prospective study. Lancet Neurol. 2005, 4:627-634.
299. Olesen J., Leonardi M. The burden of brain diseases in Europe. Eur. J. Neurol. 2003, 10:471-477.
300. Olie J.P., Levy E. Manic episodes: the direct cost of a three-month period following hospitalisation. Eur. Psychiatry 2002, 17:278-286.
301. Oliva-Moreno J., Lopez-Bastida J., Osuna-Guerrero R., Montejo-Gonzalez A.L., Duque-Gonzalez B. The costs of schizophrenia in Spain. Eur. J. Health Econ. 2006, 7:182-188.
302. Olivares J.M., Rodriguez-Martinez A., Buron J.A., onso-Escolano D., Rodriguez-Morales A. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12- and 24-month follow-up from the e-STAR database in Spain. Appl. Health Econ. Health Policy 2008, 6:41-53.
303. Oöpik M., Kaasik A.E., Jakobsen J. A population based epidemiological study on myasthenia gravis in Estonia. J. Neurol. Neurosurg. Psychiatry 2003, 74:1638-1643.
304. Orlewska E., Mierzejewski P., Zaborski J., Kruszewska J., Wicha W., Fryze W., Drozdowski W., Skibicka I., Mirowska-Guzel D., Czlonkowski A., Czlonkowska A. A prospective study of the financial costs of multiple sclerosis at different stages of the disease. Eur. J. Neurol. 2005, 12:31-39.
305. Osby U., Tiainen A., Backlund L., Edman G., Adler M., Hällgren J., Sennfält K., van Baardewijk M., Sparen P. Psychiatric admissions and hospitalization costs in bipolar disorder in Sweden. J. Affect. Disord. 2009, 115:315-322.
306. O'Shea E. The Alzheimer Society of Ireland, Implementing Policy for Dementia Care in Ireland. http://www.alzheimer.ie/eng/Resources/Research/Implementing-Policy-for-Dementia-Care-in-Ireland-The-Time-for-Action-is-Now.
307. O'Shea E., O'Reilly S. The economic and social cost of dementia in Ireland. Int. J. Geriatr. Psychiatry 2000, 15:208-218.
308. Ott A., Breteler M.M., van Harskamp F., Claus J.J., van der Cammen T.J., Grobbee D.E., Hofman A. Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study. BMJ 1995, 310:970-973.
309. Öun A., Haldre S., MÃ{currency sign}gi M. Prevalence of adult epilepsy in Estonia. Epilepsy Res. 2003, 52:233-242.
310. Packer R.J., MacDonald T., Vezina G. Central nervous system tumors. Pediatr. Clin. North Am. 2008, 55:121-145. xi.
311. Pallesen S., Nordhus I.H., Nielsen G.H., Havik O.E., Kvale G., Johnsen B.H., Skjotskift S. Prevalence of insomnia in the adult Norwegian population. Sleep 2001, 24:771-779.
312. Pallesen S., Nordhus I.H., Omvik S., Sivertsen B., Tell G.S., Bjorvatn B. Prevalence and risk factors of subjective sleepiness in the general adult population. Sleep 2007, 30:619-624.
313. Papathanasopoulos P., Gourzoulidou E., Messinis L., Georgiou V., Leotsinidis M. Prevalence and incidence of multiple sclerosis in western Greece: a 23-year survey. Neuroepidemiology 2008, 30:167-173.
314. Partinen M. Epidemiology of obstructive sleep apnea syndrome. Curr. Opin. Pulm. Med. 1995, 1:482-487.
315. Partinen M., Hublin C., Kaprio J., Koskenvuo M., Guilleminault C. Twin studies in narcolepsy. Sleep 1994, 17:S13-S16.
316. Patel A., Knapp M., Henderson J., Baldwin D. The economic consequences of social phobia. J. Affect. Disord. 2002, 68:221-233.
317. Pechevis M., Clarke C.E., Vieregge P., Khoshnood B., Deschaseaux-Voinet C., Berdeaux G., Ziegler M. Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. Eur. J. Neurol. 2005, 12:956-963.
318. Pelham W.E., Foster E.M., Robb J.A. The economic impact of attention-deficit/hyperactivity disorder in children and adolescents. J. Pediatr. Psychol. 2007, 32:711-727.
319. Peter J.H., Siegrist J., Podszus T., Mayer J., Selzer K., von Wichert P. Prevalence of sleep apnea in healthy industrial workers. Klin. Wochenschr. 1985, 63:807-811.
320. Peterlin B., Ristic S., Sepcic J., Vracko B.K., Rako A., Lovrecic L., Brajenovic-Milic B., Rudez J., Materljan E., Kapovic M. Region with persistent high frequency of multiple sclerosis in Croatia and Slovenia. J. Neurol. Sci. 2006, 247:169-172.
321. Pharmacy Sales Prices (AUP) http://www.apotekensservice.se/Global/Externa%20webben/statistik/L%c3%a4kemedel%202010/L%c3%a4kemedelsutvecklingen%202008-2010%201.0.pdf.
322. Picot M.C., Baldy-Moulinier M., Daures J.P., Dujols P., Crespel A. The prevalence of epilepsy and pharmacoresistant epilepsy in adults: a population-based study in a Western European country. Epilepsia 2008, 49:1230-1238.
323. Polder J.J., Meerding W.J., Bonneux L., van der Maas P.J. Healthcare costs of intellectual disability in the Netherlands: a cost-of-illness perspective. J. Intellect. Disabil. Res. 2002, 46:168-178.
324. Polinder S., Meerding W.J., van Baar M.E., Toet H., Mulder S., van Beeck E.F. Cost estimation of injury-related hospital admissions in 10 European countries. J. Trauma 2005, 59:1283-1290.
325. Poulas K., Tsibri E., Kokla A., Papanastasiou D., Tsouloufis T., Marinou M., Tsantili P., Papapetropoulos T., Tzartos S.J. Epidemiology of seropositive myasthenia gravis in Greece. J. Neurol. Neurosurg. Psychiatry 2001, 71:352-356.
326. Pouratian N., Schiff D. Management of low-grade glioma. Curr. Neurol. Neurosci. Rep. 2010, 10:224-231.
327. Pradalier A., Auray J.P., El H.A., Alzahouri K., Dartigues J.F., Duru G., Henry P., Lanteri-Minet M., Lucas C., Chazot G., Gaudin A.F. Economic impact of migraine and other episodic headaches in France: data from the GRIM2000 study. PharmacoEconomics 2004, 22:985-999.
328. Priebe S., Matanov A., Jankovic G.J., McCrone P., Ljubotina D., Knezevic G., Kucukalic A., Franciskovic T., Schutzwohl M. Consequences of untreated posttraumatic stress disorder following war in former Yugoslavia: morbidity, subjective quality of life, and care costs. Croat. Med. J. 2009, 50:465-475.
329. Priebe S., Gavrilovic J.J., Matanov A., Franciskovic T., Knezevic G., Ljubotina D., Mehmedbasic A.B., Schutzwohl M. Treatment outcomes and costs at specialized centers for the treatment of PTSD after the war in former Yugoslavia. Psychiatr. Serv. 2010, 61:598-604.
330. PSSRU Unit Costs of Health and Social Care 2008 2011, 41. Section 1.5.
331. Puura K., Almqvist F., Tamminen T., Piha J., Rasanen E., Kumpulainen K., Moilanen I., Koivisto A.M. Psychiatric disturbances among prepubertal children in southern Finland. Soc. Psychiatry Psychiatr. Epidemiol. 1998, 33:310-318.
332. Rahkonen T., Eloniemi-Sulkava U., Rissanen S., Vatanen A., Viramo P., Sulkava R. Dementia with Lewy bodies according to the consensus criteria in a general population aged 75years or older. J. Neurol. Neurosurg. Psychiatry 2003, 74:720-724.
333. Ranzato F., Perini P., Tzintzeva E., Tiberio M., Calabrese M., Ermani M., Davetag F., De Z.L., Garbin E., Verdelli F., Villacara A., Volpe G., Moretto G., Gallo P. Increasing frequency of multiple sclerosis in Padova, Italy: a 30year epidemiological survey. Mult. Scler. 2003, 9:387-392.
334. Reese J.P., Winter Y., Balzer-Geldsetzer M., Botzel K., Eggert K., Oertel W.H., Dodel R., Campenhausen S.V. Parkinson's disease: cost-of-illness in an outpatient cohort. Gesundheitswesen 2010, 73:22-29. Epub 2010 Mar 12.
335. Rehm J., Room R., van den Brink W., Jacobi F. Alcohol use disorders in EU countries and Norway: an overview of the epidemiology. Eur. Neuropsychopharmacol. 2005, 15:377-388.
336. Reid S., Wessely S., Crayford T., Hotopf M. Frequent attenders with medically unexplained symptoms: service use and costs in secondary care. Br. J. Psychiatry 2002, 180:248-253.
337. Rickels E., von Wild K., Wenzlaff P. Head injury in Germany: a population-based prospective study on epidemiology, causes, treatment and outcome of all degrees of head-injury severity in two distinct areas. Brain Inj. 2010, 24:1491-1504.
338. Riedel-Heller S.G., Busse A., Aurich C., Matschinger H., Angermeyer M.C. Prevalence of dementia according to DSM-III-R and ICD-10: results of the Leipzig Longitudinal Study of the Aged (LEILA75+) part 1. Br. J. Psychiatry 2001, 179:250-254.
339. Rigaud A.S., Fagnani F., Bayle C., Latour F., Traykov L., Forette F. Patients with Alzheimer's disease living at home in France: costs and consequences of the disease. J. Geriatr. Psychiatry Neurol. 2003, 16:140-145.
340. Rocca W.A., Savettieri G., Anderson D.W., Meneghini F., Grigoletto F., Morgante L., Reggio A., Salemi G., Patti F., Di Perri R. Door-to-door prevalence survey of epilepsy in three Sicilian municipalities. Neuroepidemiology 2001, 20:237-241.
341. Romeo R., Knapp M., Scott S. Economic cost of severe antisocial behaviour in children-and who pays it. Br. J. Psychiatry 2006, 188:547-553.
342. Rossi C., Simini B., Brazzi L., Rossi G., Radrizzani D., Iapichino G., Bertolini G. Variable costs of ICU patients: a multicenter prospective study. Intensive Care Med. 2006, 32:545-552.
343. Roy A.N., Smith M. Prevalence and cost of insomnia in a state Medicaid fee-for-service population based on diagnostic codes and prescription utilization. Sleep Med. 2010, 11:462-469.
344. Russo P., Capone A., Paolillo A., Macchia F., Ranzato F., Costantino G., Esposti L.D., Caprino L. Cost-analysis of relapsing-remitting multiple sclerosis in Italy after the introduction of new disease-modifying agents. Clin. Drug Investig. 2004, 24:409-420.
345. Saar I. The social costs of alcohol misuse in Estonia. Eur. Addict. Res. 2009, 15:56-62.
346. Salawu F.K., Wakil M.A., Danburam A. Overview of somatization-diagnosis and management. Niger. J. Med. 2009, 18:349-353.
347. Salize H.J., Stamm K., Schubert M., Bergmann F., Harter M., Berger M., Gaebel W., Schneider F. Cost of care for depressive disorders in primary and specialized care in Germany. Psychiatr. Prax. 2004, 31:147-156.
348. Salize H.J., McCabe R., Bullenkamp J., Hansson L., Lauber C., Martinez-Leal R., Reinhard I., Rössler W., Svensson B., Torres-Gonzalez F., van den Brink R., Wiersma D., Priebe S. Cost of treatment of schizophrenia in six European countries. Schizophr. Res. 2009, 111:70-77.
349. Salvador-Carulla L., Bertelli M. 'Mental retardation' or 'intellectual disability': time for a conceptual change. Psychopathology 2008, 41:10-16.
350. Salvador-Carulla L., Segui J., Fernandez-Cano P., Canet J. Costs and offset effect in panic disorders. Br. J. Psychiatry Suppl. 1995, 23-28.
351. Salvador-Carulla L., Bendeck M., Fernandez A., Alberti C., Sabes-Figuera R., Molina C., Knapp M. Costs of depression in Catalonia (Spain). J. Affect. Disord. 2011, 132:130-138.
352. Sancho J., Pena P., Rufo M., Palacios G., Masramon X., Rejas J. Health and non-health care resources use in the management of adult outpatients with drug-resistant epilepsy in Spain: a cost-of-illness study (LINCE study). Epilepsy Res. 2008, 81:176-187.
353. Sangrador C., Luaces R. Study of the prevalence of epilepsy among school children in Valladolid, Spain. Epilepsia 1991, 32:791-797.
354. Sasai T., Inoue Y., Komada Y., Nomura T., Matsuura M., Matsushima E. Effects of insomnia and sleep medication on health-related quality of life. Sleep Med. 2010, 11:452-457.
355. Schenk M. Dtsch. Med. Wochenschr. 2010, 135:24.
356. Schepelmann K., Winter Y., Spottke A.E., Claus D., Grothe C., Schroder R., Heuss D., Vielhaber S., Mylius V., Kiefer R., Schrank B., Oertel W.H., Dodel R. Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy. J. Neurol. 2010, 257:15-23.
357. Schrag A., Ben-Shlomo Y., Quinn N.P. Cross sectional prevalence survey of idiopathic Parkinson's disease and Parkinsonism in London. BMJ 2000, 321:21-22.
358. Schulenberg J., Schulenberg I., Horn R. Cost of treatment and cost of care for Alzheimer's disease in Germany. The Health Economics of Dementia 1998, 217-230. John Wiley & Sons Ltd., Chichester. A. Wimo (Ed.).
359. Scuvee-Moreau J., Kurz X., Dresse A. The economic impact of dementia in Belgium: results of the National Dementia Economic Study (NADES). Acta Neurol. Belg. 2002, 102:104-113.
360. Sicras-Mainar A., Blanca-Tamayo M., Gutierrez-Nicuesa L., Salvatella-Pasant J., Navarro-Artieda R. Impact of morbidity, resource use and costs on maintenance of remission of major depression in Spain: a longitudinal study in a population setting. Gac. Sanit. 2010, 24:13-19.
361. Sidenvall R., Forsgren L., Heijbel J. Prevalence and characteristics of epilepsy in children in northern Sweden. Seizure 1996, 5:139-146.
362. Silber M.H., Krahn L.E., Olson E.J., Pankratz V.S. The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. Sleep 2002, 25:197-202.
363. Sillanpää M. Medico-social prognosis of children with epilepsy. Epidemiological study and analysis of 245 patients. Acta Paediatr. Scand. Suppl. 1973, 237:3-104.
364. Sivertsen B., Overland S., Neckelmann D., Glozier N., Krokstad S., Pallesen S., Nordhus I.H., Bjorvatn B., Mykletun A. The long-term effect of insomnia on work disability: the HUNT-2 historical cohort study. Am. J. Epidemiol. 2006, 163:1018-1024.
365. Sivertsen B., Krokstad S., Mykletun A., Overland S. Insomnia symptoms and use of health care services and medications: the HUNT-2 study. Behav. Sleep Med. 2009, 7:210-222.
366. Sivertsen B., Krokstad S., Overland S., Mykletun A. The epidemiology of insomnia: associations with physical and mental health. The HUNT-2 study. J. Psychosom. Res. 2009, 67:109-116.
367. Sivertsen B., Nordhus I.H., Bjorvatn B., Pallesen S. Sleep problems in general practice: a national survey of assessment and treatment routines of general practitioners in Norway. J. Sleep Res. 2010, 19:36-41.
368. Smestad C., Sandvik L., Holmoy T., Harbo H.F., Celius E.G. Marked differences in prevalence of multiple sclerosis between ethnic groups in Oslo, Norway. J. Neurol. 2008, 255:49-55.
369. Smit F., Cuijpers P., Oostenbrink J., Batelaan N., de Graaf R., Beekman A. Costs of nine common mental disorders: implications for curative and preventive psychiatry. J. Ment. Health Policy Econ. 2006, 9:193-200.
370. Smith S., Horgan F., Sexton E., Cowman S., Hickey A., Kelly P., McGee H., Murphy S., O'Neill D., Royston M., Shelley E., Wiley M. Cost of Stroke in Ireland: Estimating the Annual Economic Cost of Stroke and TIA in Ireland 2010.
371. Sobocki P., Lekander I., Berwick S., Olesen J., Jonsson B. Resource allocation to brain research in Europe (RABRE). Eur. J. Neurosci. 2006, 24:2691-2693.
372. Soeteman D.I., Hakkaart-van R.L., Verheul R., Busschbach J.J. The economic burden of personality disorders in mental health care. J. Clin. Psychiatry 2008, 69:259-265.
373. Solaro C., Allemani C., Messmer U.M., Canevari E., Dagnino N., Pizio R., Regesta G., Tanganelli P., Battaglia M.A., Mancardi G.L. The prevalence of multiple sclerosis in the north-west Italian province of Genoa. J. Neurol. 2005, 252:436-440.
374. Souetre E., Lozet H., Cimarosti I., Martin P., Chignon J.M., Ades J., Tignol J., Darcourt G. Cost of anxiety disorders: impact of comorbidity. J. Psychosom. Res. 1994, 38(Suppl. 1):151-160.
375. Souetre E.J., Qing W., Vigoureux I., Dartigues J.F., Lozet H., Lacomblez L., Derouesne C. Economic analysis of Alzheimer's disease in outpatients: impact of symptom severity. Int. Psychogeriatr. 1995, 7:115-122.
376. Spottke A.E., Reuter M., Machat O., Bornschein B., von Campenhausen S., Berger K., Koehne-Volland R., Rieke J., Simonow A., Brandstaedter D., Siebert U., Oertel W.H., Ulm G., Dodel R. Cost of illness and its predictors for Parkinson's disease in Germany. PharmacoEconomics 2005, 23:817-836.
377. Steinhausen H.C., Metzke C.W., Meier M., Kannenberg R. Prevalence of child and adolescent psychiatric disorders: the Zurich Epidemiological Study. Acta Psychiatr. Scand. 1998, 98:262-271.
378. Stiller C.A., Bunch K.J. Brain and spinal tumours in children aged under two years: incidence and survival in Britain, 1971-85. Br. J. Cancer Suppl. 1992, 18:S50-S53.
379. Stovner L.J., Andree C. Prevalence of headache in Europe: a review for the Eurolight project. J. Headache Pain 2010, 11:289-299.
380. Stranjalis G., Bouras T., Korfias S., Andrianakis I., Pitaridis M., Tsamandouraki K., Alamanos Y., Sakas D.E., Marmarou A. Outcome in 1000 head injury hospital admissions: the Athens head trauma registry. J. Trauma 2008, 65:789-793.
381. Stranjalis G., Tsamandouraki K., Gazonis S., Martzoukos A., Mavroforou E., Metallinos A., Ovales C., Papoulias E., Spigos C., Voulgaris A., Sakas D., Alamanos Y. Low occurrence of epileptic seizures and epilepsy in a defined area of Northwest Greece. Seizure 2009, 18:206-210.
382. Strassels S.A. Economic burden of prescription opioid misuse and abuse. J. Manag. Care Pharm. 2009, 15:556-562.
383. Struijs J.N., van Genugten M.L., Evers S.M., Ament A.J., Baan C.A., van den Bos G.A. Future costs of stroke in the Netherlands: the impact of stroke services. Int. J. Technol. Assess. Health Care 2006, 22:518-524.
384. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., Curschmann J., Janzer R.C., Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross J.G., Eisenhauer E., Mirimanoff R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352:987-996.
385. Sumelahti M.L., Tienari P.J., Wikstrom J., Palo J., Hakama M. Increasing prevalence of multiple sclerosis in Finland. Acta Neurol. Scand. 2001, 103:153-158.
386. Sveen M.L., Schwartz M., Vissing J. High prevalence and phenotype-genotype correlations of limb girdle muscular dystrophy type 2I in Denmark. Ann. Neurol. 2006, 59:808-815.
387. Svendsen T., Lossius M., Nakken K.O. Age-specific prevalence of epilepsy in Oppland County, Norway. Acta Neurol. Scand. 2007, 116:307-311.
388. Swingler R.J., Davidson D.L., Roberts R.C., Moulding F. The cost of epilepsy in patients attending a specialist epilepsy service. Seizure 1994, 3:115-120.
389. Tafalla M., Salvador-Carulla L., Saiz-Ruiz J., Diez T., Cordero L. Pattern of healthcare resource utilization and direct costs associated with manic episodes in Spain. BMC Psychiatry 2010, 10:31.
390. Tagliaferri F., Compagnone C., Korsic M., Servadei F., Kraus J. A systematic review of brain injury epidemiology in Europe. Acta Neurochir. (Wien.) 2006, 148:255-268. cbe.
391. Taylor E., Sandberg S. The Epidemiology of Childhood Hyperactivity 1991, Oxford University Press, Oxford.
392. Teculescu D., Hannhart B., Cornette A., Montaut-Verient B., Virion J.M., Michaely J.P. Prevalence of habitual snoring in a sample of French males. Role of "minor" nose-throat abnormalities. Respiration 2001, 68:365-370.
393. Tetto A., Manzoni P., Millul A., Beghi E., Garattini L., Tartara A., Avanzini G. The costs of epilepsy in Italy: a prospective cost-of-illness study in referral patients with disease of different severity. Epilepsy Res. 2002, 48:207-216.
394. The Health and Social Care Information Centre Statistics on Alcohol, England http://www.ic.nhs.uk/webfiles/publications/alcoholeng2009/Final%20Format%20draft%202009%20v7.pdf.
395. Thomas C.M., Morris S. Cost of depression among adults in England in 2000. Br. J. Psychiatry 2003, 183:514-519.
396. Web of Knowledge THOMSON REUTERS (ISI). http://portal.isiknowledge.com/.
397. Tidman L., Saravanan K., Gibbs J. Epilepsy in mainstream and special educational primary school settings. Seizure 2003, 12:47-51.
398. Tison F., Dartigues J.F., Dubes L., Zuber M., Alperovitch A., Henry P. Prevalence of Parkinson's disease in the elderly: a population study in Gironde, France. Acta Neurol. Scand. 1994, 90:111-115.
399. Tognoni G., Ceravolo R., Nucciarone B., Bianchi F., Dell'Agnello G., Ghicopulos I., Siciliano G., Murri L. From mild cognitive impairment to dementia: a prevalence study in a district of Tuscany, Italy. Acta Neurol. Scand. 2005, 112:65-71.
400. Trabucchi M. An economic perspective on Alzheimer's disease. J. Geriatr. Psychiatry Neurol. 1999, 12:29-38.
401. Troxel W.M., Buysse D.J., Matthews K.A., Kravitz H.M., Bromberger J.T., Sowers M., Hall M.H. Marital/cohabitation status and history in relation to sleep in midlife women. Sleep 2010, 33:973-981.
402. Truelsen T., Piechowski-Jozwiak B., Bonita R., Mathers C., Bogousslavsky J., Boysen G. Stroke incidence and prevalence in Europe: a review of available data. Eur. J. Neurol. 2006, 13:581-598.
403. Tsolaki M., Fountoulakis C., Pavlopoulos I., Chatzi E., Kazis A. Prevalence and incidence of Alzheimer disease and other dementing disorders in Pylea, Greece. Am. J. Alzheimers Dis. 1999, 14:138-149.
404. Uhl A., Bachmayer S., Kobrna U., Puhm A., Springer A., Kopf N., et al. Handbuch: Alkohol - Österreich: Zahlen, Daten, Fakten, Trends 2009 2009, dritte überarbeitete und ergänzte Auflage. Wein, Austria: BMGFJ.
405. Ursin R., Baste V., Moen B.E. Sleep duration and sleep-related problems in different occupations in the Hordaland Health Study. Scand. J. Work Environ. Health 2009, 35:193-202.
406. van Asselt A.D., Dirksen C.D., Arntz A., Severens J.L. The cost of borderline personality disorder: societal cost of illness in BPD-patients. Eur. Psychiatry 2007, 22:354-361.
407. van Hout B., Gagnon D., Souetre E., Ried S., Remy C., Baker G., Genton P., Vespignani H., McNulty P. Relationship between seizure frequency and costs and quality of life of outpatients with partial epilepsy in France, Germany, and the United Kingdom. Epilepsia 1997, 38:1221-1226.
408. van Mill J.G., Hoogendijk W.J., Vogelzangs N., van Dyck R., Penninx B.W. Insomnia and sleep duration in a large cohort of patients with major depressive disorder and anxiety disorders. J. Clin. Psychiatry 2010, 71:239-246.
409. Verhulst F.C., van der Ende J., Ferdinand R.F., Kasius M.C. The prevalence of DSM-III-R diagnoses in a national sample of Dutch adolescents. Arch. Gen. Psychiatry 1997, 54:329-336.
410. Vgontzas A.N., Liao D., Pejovic S., Calhoun S., Karataraki M., Bixler E.O. Insomnia with objective short sleep duration is associated with type 2 diabetes: a population-based study. Diabetes Care 2009, 32:1980-1985.
411. von Campenhausen S., Winter Y., Gasser J., Seppi K., Reese J.P., Pfeiffer K.P., Geiger-Gritsch S., Botzel K., Siebert U., Oertel W.H., Dodel R., Poewe W. Cost of illness and health service patterns in Morbus Parkinson in Austria. Wien. Klin. Wochenschr. 2009, 121:574-582.
412. Waage S., Moen B.E., Pallesen S., Eriksen H.R., Ursin H., Akerstedt T., Bjorvatn B. Shift work disorder among oil rig workers in the North Sea. Sleep 2009, 32:558-565.
413. Waaler P.E., Blom B.H., Skeidsvoll H., Mykletun A. Prevalence, classification, and severity of epilepsy in children in western Norway. Epilepsia 2000, 41:802-810.
414. Wasserfallen J.B., Ostermann S., Leyvraz S., Stupp R. Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death. Neuro. Oncol. 2005, 7:189-195.
415. Wellis G., Nagel R., Vollmar C., Steiger H.J. Direct costs of microsurgical management of radiosurgically amenable intracranial pathology in Germany: an analysis of meningiomas, acoustic neuromas, metastases and arteriovenous malformations of less than 3cm in diameter. Acta Neurochir. (Wien.) 2003, 145:249-255.
416. Whiteneck G., Brooks C.A., Mellick D., Harrison-Felix C., Terrill M.S., Noble K. Population-based estimates of outcomes after hospitalization for traumatic brain injury in Colorado. Arch. Phys. Med. Rehabil. 2004, 85:S73-S81.
417. WHO Europe European Status Report on Alcohol and Health http://www.euro.who.int/__data/assets/pdf_file/0004/128065/e94533.pdf.
418. Wilking N., Jönsson B. A Pan-European Comparison Regarding Patient Access to Cancer Drugs 2005, Karolinska Institutet and Stockholm School of Economics.
419. Wilking N., Jönsson B., Högberg D., Justo N. Comparator Report on Patient Access to Cancer Drugs in Europe http://www.comparatorreports.se/Cancer%20report%20EFPIA%20Final%20summary%20slides%20Jan%2027.pdf.
420. Wilms H.U., Mory C., Angermeyer M.C. Illness related costs for spouses of patients suffering from a mental illness: results of a study with repeated measurements. Psychiatr. Prax. 2004, 31:177-183.
421. Wimo A., Jonsson L., Gustavsson A., McDaid D., Ersek K., Georges J., Gulacsi L., Karpati K., Kenigsberg P., Valtonen H. The economic impact of dementia in Europe in 2008-cost estimates from the Eurocode project. Int. J. Geriatr. Psychiatry 2010, 2010 Oct 28 [Epub ahead of print].
422. Wing Y.K., Li R.H., Lam C.W., Ho C.K., Fong S.Y., Leung T. The prevalence of narcolepsy among Chinese in Hong Kong. Ann. Neurol. 2002, 51:578-584.
423. Winter Y., von Campenhausen S., Brozova H., Skoupa J., Reese J.P., Bötzel K., Eggert K., Oertel W.H., Dodel R., Ruzicka E. Costs of Parkinson's disease in eastern Europe: a Czech cohort study. Parkinsonism Relat. Disord. 2010, 16:51-56.
424. Winter Y., von Campenhausen S., Reese J.P., Balzer-Geldsetzer M., Longo K., Spiga G., Boetzel K., Eggert K., Oertel W.H., Dodel R., Barone P. Costs of Parkinson's disease and antiparkinsonian pharmacotherapy: an Italian cohort study. Neurodegener. Dis. 2010, 7:365-372.
425. Wittchen H.U., Jacobi F. Size and burden of mental disorders in Europe-a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol. 2005, 15:357-376.
426. Wittchen H.U., Uhmann S. The timing of depression: an epidemiological perspective. Medicographia 2010, 32(2):155-125.
427. Wittchen H.U., Behrendt S., Hofler M., Perkonigg A., Lieb R., Buhringer G., Beesdo K. What are the high risk periods for incident substance use and transitions to abuse and dependence? Implications for early intervention and prevention. Int. J. Methods Psychiatr. Res. 2008, 17(Suppl. 1):S16-S29.
428. Wittchen H.U., Beesdo-Baum K., Gloster A.T., Hofler M., Klotsche J., Lieb R., Beauducel A., Buhner M., Kessler R.C. The structure of mental disorders re-examined: is it developmentally stable and robust against additions?. Int. J. Methods Psychiatr. Res. 2009, 18:189-203.
429. Wittchen H.U., Gloster A., Beesdo K., Schonfeld S., Perkonigg A. Posttraumatic stress disorder: diagnostic and epidemiological perspectives. CNS Spectr. 2009, 14:5-12.
430. Wittchen H.U., Jacobi F., Rehm J., Gustavsson A., Svensson M., Jönsson B., Olesen J., Allgulander C., Alonso J., Faravelli C., Fratiglioni L., Jennum P., Lieb R., Maercker A., van Os J., Preisig M., Salvador-Carulla L., Simon R., Steinhausen H.C. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol. 2011, 21:655-679.
431. Wolstenholme J., Fenn P., Gray A., Keene J., Jacoby R., Hope T. Estimating the relationship between disease progression and cost of care in dementia. Br. J. Psychiatry 2002, 181:36-42.
432. Wrensch M., Minn Y., Chew T., Bondy M., Berger M.S. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro. Oncol. 2002, 4:278-299.
433. Young T. Sleep-disordered breathing in older adults: is it a condition distinct from that in middle-aged adults?. Sleep 1996, 19:529-530.
434. Young T., Palta M., Dempsey J., Skatrud J., Weber S., Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N. Engl. J. Med. 1993, 328:1230-1235.
435. Young T., Blustein J., Finn L., Palta M. Sleep-disordered breathing and motor vehicle accidents in a population-based sample of employed adults. Sleep 1997, 20:608-613.
436. Young T., Evans L., Finn L., Palta M. Estimation of the clinically diagnosed proportion of sleep apnea syndrome in middle-aged men and women. Sleep 1997, 20:705-706.
437. Young T., Peppard P., Palta M., Hla K.M., Finn L., Morgan B., Skatrud J. Population-based study of sleep-disordered breathing as a risk factor for hypertension. Arch. Intern. Med. 1997, 157:1746-1752.
438. Young T., Peppard P.E., Gottlieb D.J. Epidemiology of obstructive sleep apnea: a population health perspective. Am. J. Respir. Crit. Care Med. 2002, 165:1217-1239.
439. Zaloshnja E., Miller T., Langlois J.A., Selassie A.W. Prevalence of long-term disability from traumatic brain injury in the civilian population of the United States, 2005. J. Head Trauma Rehabil. 2008, 23:394-400.
440. Zambori J., Szadoczky E., Rozsa S., Furedi J. Cost-outcome of anxiety treatment intervention in primary care in Hungary. J. Ment. Health Policy Econ. 2002, 5:115-120.
441. Zielinski J.J. Epilepsy and mortality rate and cause of death. Epilepsia 1974, 15:191-201.